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Introduction: Acquired resistance to glucocorticoids constitutes a major clinical challenge, often overlooked in
the search for compounds to improve the effect of classic steroids. We sought to unravel how a plant-original
compound, ginsenoside Rh1, potentiates dexmethasone (DEX)’s potential anti-inflammation properties.
Methods: Ginsenoside Rh1 combined with DEX was applied in a short-term and long-term treatment protocol for
inflammation. Its potential mechanism on anti-inflammation was explored. In addition, the effect of Rh1 on the
side-effect induced by DEX was studied. Furthermore, the in vivo anti-inflammatory effects of Rh1 combined with
DEX were evaluated in a collagen-induced arthritis (CIA) mice model.
Results: Ginsenoside Rh1 potentiates DEX’s anti-inflammatory effects even after prolonged DEX treatment. Rh1 could
improve the glucocorticoid receptor (GR)’s transrepression on nuclear factor kappa B (NF-κB) and transactivation on
dual specificity protein phosphatase 1 (DUSP1), which is responsible for DEX’s anti-inflammatory effects. Parallel Western
blot assay and radioligand binding analysis revealed that Rh1 could increase the expression and binding of GR. This is
in sharp contrast to DEX alone, showing a direct link among prolonged treatment, decreasing GR and the abolishment
of anti-inflammation. Interestingly, Rh1 does not enhance the transactivation of glucocorticoid-responsive elements
(GRE) driven genes - gluconeogenic enzyme glucose-6-phosphatase (G6P) and phosphoenolpyruvate carboxykinasee
phosphatase (PEPCK) in primary mouse hepatocytes, a mechanism partly held accountable for the metabolic
side-effects. Similar results were found in CIA mice.
Conclusion: Rh1 could potentiate DEX’s anti-inflammatory effects and does not cause a hyperglycemic side effect.
Ginsenoside Rh1 combined with DEX may be a promising candidate treatment option for chronic inflammatory
diseases in need of long-term immunosuppression therapies.Introduction
Glucocorticoids (GCs) are still the cornerstone drugs
used in treatment protocols of a wide range of inflam-
matory and immune disorders. However, long-term and/
or high-dose GC administration is commonly associated
with adverse side effects, such as hyperglycemia, weight
gain, osteoporosis, depression and decreased immuno-
logical function. Furthermore, patients on glucocorti-
coids can develop reduced glucocorticoid sensitivity and* Correspondence: wangchenchina@126.com; lingchangquan@hotmail.com
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reproduction in any medium, provided the oreven resistance. It has been reported that approximately
30% of patients failed to respond to even high doses of
glucocorticoids [1,2].
Different molecular mechanisms have been responsible
for the phenomenon of acquired glucocorticoid resistance,
including reduced expression of the glucocorticoid recep-
tor (GR), altered affinity of GR for the ligand, reduced
ability of GR to bind DNA or increased expression of
inflammatory transcription factors, such as AP-1, that
compete for DNA binding [3-5].
Current research is focused on finding compounds
with similar anti-inflammatory potency of the standard
GCs but with reduced side effects [6-9]. Nevertheless, ithis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from repression of GR in a ligand will result in a beneficial
therapeutic profile. Actually, the powerful anti-inflamma-
tory effect of GCs is complex, and likely due to both re-
pression of a large number of pro-inflammatory cytokines
and mediators, as well as activation of anti-inflammatory
genes, such as IL-10, IL-4,TGF-β, DUSP1 and Annexin A1
[10-12]. As a result, novel compounds that lack a capacity
for steroid-inducible genes may in fact show lessened
anti-inflammatory effects [13-15]. In fact, the regulation of
GR may be another efficient strategy for restoring gluco-
corticoid resistance.
Over the past years, our team has had a continued
interest in the regulation of GR with Chinese medicinal
herbs [16,17]. We have demonstrated that the main
extracts of ginseng, ginsenosides (GSS), which is one of
the derivatives of triterpenoid dammarane consisting of
30 carbon atoms, could partially reverse dexmethasone
(DEX)-induced down-regulation of GR in vitro and
in vivo [18]. But there are many ingredients in GSS.
Ginsenoside Rh1 is one of the major one of these.
We thus studied the effect of ginsenoside Rh1 on GR
and how this compound improved DEX’s anti-inflam-
matory potential by regulating GR after prolonged DEX
treatment. In addition, we unraveled the potential of
Rh1 on GCs-induced hyperglycemia. Also, we evaluated




Recombinant murine TNF-α was purchased from R&D.
Ginsenoside Rh1 was supplied by Shanghai Dongfang
Pharmaceutical (Shanghai, China). Rabbit polyclonal Ab
to GR was obtained from Abcam (Cambridge, MA, USA).
Phospho-IκBa (Ser32) rabbit mAb, phospho-NF-κB p65
(Ser536), phospho-p38, IκBa (44D4) rabbit mAb, NF-κB
p65 and p38 Abs were supplied by Cell Signaling Tech-
nology (Danvers, MA, USA).
Cell culture
The murine macrophage RAW264.7 cells were purchased
from American Type Culture Collection (Manassas, VA,
USA) and maintained in Dulbecco’s modified Eagle’s me-
dium (DMEM) (Invitrogen, Carlsbad, CA, USA) supple-
mented with 10% FBS, 100 U/ml penicillin, and 0.1 mg/ml
streptomycin in a 5% CO2 humidified incubator at 37°C.
The primary mouse hepatocytes were isolated and cultured
as described in [19].
Western blot analysis
Cells were seeded in six-well plates. Total protein, cyto-
plasmic and nuclear proteins were extracted as described
previously [20].Real-time PCR
RT-PCR was performed as described in [21]. Primer sets
for interleukin-6 (IL-6), IL-17, matrix matalloproteinase-1
(MMP-1), tumor necrosis factor-alpha (TNF-α), phos-
phoenolpyruvate carboxykinasee phosphatase (PEPCK),
gluconeogenic enzyme glucose-6-phosphatase (G6P), dual
specificity protein phosphatase 1 (DUSP-1), GR and gly-
ceraldehyde 3-phosphate dehydrogenase (GAPDH) are
available upon request.
ELISA
IL-6 and IL-17 levels were determined by ELISA kits
according to the manufacturer’s instructions (Bender
MedSystems, Vienna, Austria).
Radioligand binding analysis for GR
Radioligand binding analysis was performed as described
in [18].
Transient transfection and luciferase assay
After RAW264.7 cells reached 90 to 95% confluence in 24-
well dishes, they were transfected using Lipofectamine 2000
(Invitrogen) with 0.6 mg/ml p-GR-Luc and 0.08 mg/ml
p-Renilla luciferase-thymidine kinase for normalization in
serum-free medium. Four hours later, the medium was re-
placed with DMEM containing 10% FBS. Twenty-four
hours post-transfection, cells were pretreated for 1 h with
or without 10 μM Rh1, after which DEX (1 μM) was
added for 24 h. Then the reporter gene activity was
measured according to the recommendation of the manu-
facturer (Promega, Madison, WI, USA). Results were
normalized by thymidine kinase reporter activity.
Collagen-induced arthritis mouse model
Male DBA/1 mice (six to eight weeks old) were purchased
from the Second Military Medical University Laboratory
Animal Center (Shanghai, China). The induction of colla-
gen-induced arthritis (CIA) in DBA/1 mice is described in
[22,23]. Once arthritis was evident, the animals were ran-
domized in one of the following treatment groups with
eight mice per group: vehicle, Rh1 and DEX, and DEX by
intraperitoneal (i.p.) therapy for 10 d. An additional eight
normal mice were as blank group. The clinical severity of
arthritic paws was graded according to standard evalu-
ation procedures. For more details refer to [22].
All procedures involving animals were performed in
accordance with the European Communities Council
Directive of November 24, 1986 (86/609 EEC) and ap-
proved by the Ethics Committee of Changhai Hospital.
Blood glucose determination
Food was removed overnight. Blood samples were taken
by caudal vein puncture under ethyl ether anesthesia.
Blood glucose levels were determined by CareSens blood
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cording to the manufacturer’s instructions.
Histological evaluation
Knees were dissected post-mortem, fixed in 10% formalized
saline, decalcified, dehydrated and embedded in paraffin.
Sections of 5 μm were made and stained with hematoxylin-
eosin staining. Serial sections were evaluated by two
blinded investigators. The inflammatory metacarpophalan-
geal joints were analyzed according to different parameters,
including the influx of inflammatory cells in joint capsules,
cartilage destruction, joint cavity narrowing, influx of in-
flammatory cells in marrow cavities and periosteal
thickening.
All procedures involving animals were performed in ac-
cordance with the European Communities Council Direct-
ive of November 24, 1986 (86/609 EEC) and approved by
the Ethics Committee of Changhai Hospital.
Statistical analysis
All data were presented as the means ± standard devia-
tion (S.D). Statistical significance was determined using
SPSS 11.0 for Windows from SPSS Inc. Chicago, Illinois,
USA. Data analysis was performed by one-way analysis
of variance (ANOVA), followed by Fisher’s least signifi-
cant difference (LSD). Differences with P-values <0.05
were considered to be statistically significant.
Results
Ginsenoside Rh1 combined with DEX inhibited the
expression of pro-inflammatory cytokines, even after
long-time treatment
Our recent research showed that ginsenoside Rh1 could
reverse the reduction of GR expression and binding ca-
pacity induced by DEX (Additional file 1: Figure S1). And
in the presence of 10 μM Rh1, the reversal effect was the
most significant.
In order to observe if Rh1 could improve the anti-
inflammatory potential of DEX, we compared the the-
rapeutic potential of both treatment protocols (Rh1
combined with DEX and DEX treatment alone) in two
different experimental settings. First, we pretreated the
RAW264.7 cells with solvent, DEX (1 μM) or DEX com-
bined with Rh1 (10 μM, 1 μM, 0.1 μM) or Rh1 alone for
2 h, after which TNF-α (20 ng/ml) was added for 8 h.
The anti-inflammatory agents thus resided on the cells
for a time span of 10 h, hereby mimicking a short-term
treatment protocol. Alternatively, we pretreated the
cells with solvent, DEX (1 μM) or DEX combined with
Rh1 (10 μM, 1 μM, 0.1 μM ) or Rh1 alone for 24 h, after
which TNF-α was added for 8 h. The anti-inflammatory
agents were thus kept on the cells for 32 h, reflecting a
prolonged treatment protocol.The pro-inflammatory mediators IL-6, IL-17, MMP-1
and TNF-α were chosen to evaluate the anti-inflammatory
potential. We observed that DEX alone was sufficient
to down-regulate the TNF-α-induced gene expression of
IL-6, IL-17, MMP-1 and TNF-α for a short treatment, but
was insufficient after a prolonged treatment. Interestingly,
Rh1 (10 μM) combined with DEX treatment, even after
prolonged treatment, efficiently repressed the expression
of IL-6, IL-17, MMP-1 and TNF-α (Figure 1A). Similar
results were found on the protein expression of IL-6 and
IL-17 (Figure 1B). It is worth noting that Rh1 treatment
alone could not repress the TNF-induced cytokines. No
obvious inhibition in cell viability was observed in any
experimental settings (Additional file 2: Figure S2).
Ginsenoside Rh1 increased DEX induced inactivation of
NF-κB and activation of DUSP1
Because Rh1 could promote the anti-inflammatory po-
tential of DEX after long-time treatment, we tested whe-
ther this inhibition is partly dependent on inactivation of
NF-κB or activation of DUSP1. The data showed that
DEX could efficiently prevent the translocation of p65
from cytoplasm to nucleus in a short treatment protocol
(lane 5 vs 4 in Figure 2A) but not in a prolonged treat-
ment protocol (lane 5 vs 4 in Figure 2B). In contrast, even
after prolonged treatment, Rh1 combined with DEX was
still able to efficiently inhibit the translocation of p65 (lane
6 vs 4 in Figure 2B). Furthermore, phospho-IκBα and total
IκBα protein levels were assessed. In the short treatment
protocol, either DEX alone or Rh1 combined with DEX
could result in a decrease of phospho-IκBα (lane 5, 6 vs 4,
lane 8, 9 vs 7 in Figure 2C). When administered for a pro-
longed time, DEX alone failed to inactivate IκBα (lanes 5
vs 4, lanes 8 vs lane 7 in Figure 2D). However, Rh1 com-
bined with DEX was still able to dephosphorylate IκBα
efficiently, even after prolonged treatment, which was
accordant to the result of p65 (lane 6 vs lane 4, lane 9 vs
lane7 in Figure 2D).
Another mechanism by which glucocorticoids inhibit
inflammation is through induction of DUSP1. Figure 2E
showed that either in short-term treatment or pro-
longed treatment protocol, DEX could increase the
transcription of DUSP1 with or without TNF-α. It was
worth noting that the degree of activation of DUSP1 by
DEX in 24 h-treatment group is lower than those in the
2 h-treatment group. More important, Rh1 could en-
hance DEX-induced DUSP1 expression in both pro-
tocols. However, Rh1 alone had no effect on the
transcription of DUSP1.
Ginsenoside Rh1 potentiated DEX induced inactivation
of p38
As MAPK phosphatase 1, DUSP1 can dephosphorylate
p38, playing an important role in the stimulation of the
Figure 1 Effects of ginsenoside Rh1 combined with DEX on TNF-induced cytokine production. RAW264.7 cells were pretreated with
solvent, DEX (1 μM) or DEX combined with Rh1 (10 μM, 1 μM, 0.1 μM ) or Rh1 alone for 2 h (short-term treatment protocol) or 24 h (prolonged
treatment protocol), as indicated in the figures. Afterwards, TNF (20 ng /ml) was added for 8 h. (A) Expression of the pro-inflammatory mediators
IL-6, IL-17, MMP-1 and TNF-α was monitored by means of quantitative PCR. Gene expression of the housekeeping gene β-actin was used for
normalization. (B) Protein expression of IL-6 and IL-17 were also determined by ELISA. Statistical significance was determined by one-way analysis
of variance (*P <0.05, **P <0.01 versus TNF group; #P <0.05, ##P <0.01 versus the DEX group). The experiments were replicated three times, and
results are representative of at least three independent induction experiments. DEX, dexamethasone; IL, interleukin; MMP-1, matrix
matalloproteinase-1; TNF, tumor necrosis factor.
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on GR ligand binding. The effect of Rh1 on p38 MAPK
was investigated for the increase of Rh1 on DEX-
induced DUSP1. As expected, stimulation of RAW264.7
cells with TNF-α for 15 and 30 minutes resulted in sig-
nificant increases in p38 activation (lanes 5 and 8 vs lane
1 to 4 in Figure 3A, B). DEX treatment alone inhibited
TNF-α induced activation of p38 in a short treatment
protocol (lanes 6 vs 5, lanes 9 vs 8 in Figure 3A), but
not in a prolonged protocol (lanes 6 vs 5, lanes 9 vs 8 in
Figure 3B). However, Rh1 combined with DEX was still
able to dephosphorylate p38 efficiently even after pro-
longed treatment (lane 7 vs 5, lane 10 vs 8 in Figure 3B).
These analyses were also quantified by ImageQuant
(Additional file 3: Figure S3).Improvement of GR was responsible for ginsenoside Rh1
enhancing the anti-inflammatory potential of DEX after
long-time treatment
To observe the correlation between the GR and anti-
inflammatory potential of Rh1 combined with DEX, a
parallel Western blot experiment and saturation binding
analysis were performed. The results confirmed that, in
the prolonged treatment protocol, DEX-induced down-
regulation of the GR expression and binding capacity be-
came more pronounced than those in the short-term
treatment protocol, thereby explaining the abolishment
of its anti-inflammatory effects. However, Rh1 combined
with DEX could partially reverse the decreased GR ex-
pression and binding affinity in RAW 264.7 cells, and this
was reflected by its efficiency in anti-inflammation, even
Figure 2 Effects of ginsenoside Rh1 combined with DEX on TNF-induced NF-κB translocation and DUSP1 activation. After pretreatment
with solvent, DEX (1 μM), or Rh1 (10 μM) combined with DEX for 2 h or 24 h, (A-B) TNF (20 ng /ml) was added for 30 minutes and localization of p65
was determined by Western blot. (C-D) TNF was added for the indicated time periods (15 and 30 minutes) and expression of phospho-IκBα and total
IκBα was determined. The experiment was replicated three times. (E) After pretreatment with solvent, DEX, Rh1 combined with DEX, or Rh1 for 2 h or
24 h, TNF was added for 2 h and DUSP1 was determined by means of quantitative PCR. Gene expression of the housekeeping gene β-actin was used
for normalization. Statistical significance was determined by one-way analysis of variance (*P <0.01 versus Control; #P <0.05, ##P <0.01 versus DEX
group; ΔP <0.05, ΔΔP <0.01 versus TNF group; &P <0.05, &&P <0.01 versus TNF + DEX group). The experiments were replicated three times, and the
results are representative of at least two independent induction experiments. DEX, dexamethasone; DUSP1, dual specificity protein phosphatase 1;
TNF, tumor necrosis factor.
Figure 3 Effects of ginsenoside Rh1 combined with DEX on p38 activation. After pretreatment with solvent, DEX (1 μM), or Rh1 (10 μM)
combined with DEX for 2 h or 24 h, TNF (20 ng /ml) was added for the indicated times (15 and 30 minutes) and expression of phospho-p38 and total
p38 was determined by Western blot. The experiment was replicated three times, and the results are representative of at least two independent
induction experiments. DEX, dexamethasone; TNF, tumor necrosis factor.
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Furthermore, co-treatment of Rh1 with an inhibitor of
mRNA transcription, actinomycin-D (0.25, 0.5, 1 ng/ml)
or with an inhibitor of protein synthesis, cycloheximide
(5, 2, 1 μg/ml), abolished the Rh1-induced up-regulation
of GR (Figure 4C, D), suggesting that mRNA transcription
and the new protein synthesis were both involved in the
effect of Rh1 on GR.
Ginsenoside Rh1 exhibited a little promotion on GRE
promotor activity but played different roles on
GRE-driven genes expression
For GR up-regulation being associated with enhancement
of GRE promoter activity, we evaluate the GRE promoter
activity by luciferase assay analysis. It seems that Rh1
could enhance the DEX-induced GRE promoter activity
slightly in RAW264.7 cells and the primary mouse hepa-
tocytes (Figure 5A). Interestingly, although Rh1 couldFigure 4 Effects of ginsenoside Rh1 combined with DEX on GR. (A-B)
with DEX for 2 h or 24 h, TNF (20 ng/ml) was added for 8 h. (A) Western b
antibody. The detection of β-actin was used as a loading control. (B) Speci
RAW264.7 cells (1 × 106) were incubated 3 h with 10−6 M [3H] DEX, with or
*P <0.05, **P <0.01 versus control, #P <0.01 versus DEX group. (C-D) RAW2
DEX for 24 h. (C) Transcription was then stopped by addition of actinomyc
assessed by means of quantitative PCR. β-actin was used for normalization
electrophoretic figures. *P <0. 01 versus control; #P <0.01 versus DEX group
by addition of cycloheximide (5, 2, 1 μg/ml) in the presence of Rh1. GR levels
a loading control. The experiment was replicated three times and results are r
dexamethasone; GR, glucocorticoid receptor; TNF, tumor necrosis factor.enhance DEX induced DUSP1 expression, Rh1 treatment
alone or Rh1 combined with DEX could not enhance the
expression of PEPCK or G6P in primary mouse hepato-
cytes, which was different from DEX. It seems that Rh1
could inhibit the expression of PEPCK or G6P in the he-
patocytes which stimulated by DEX (Figure 5B).
Ginsenoside Rh1 combined with DEX markedly
attenuated inflammation in CIA model
To evaluate the in vivo potency of Rh1 combined with
DEX to suppress Ag-driven immune responses, we
examined its effect in CIA. No differences either in the
mean severity or in the time to onset of arthritis could be
observed. Although the DEX-treated mice showed a
steady decrease in clinical severity over time, more notable
anti-inflammatory responses in the Rh1 combined with
DEX-treated mice were observed, as compared with DEX
treatment alone. Either in the mean anti-inflammatoryAfter pretreatment with solvent, DEX (1 μM) or Rh1 (10 μM) combined
lot analysis was performed in parallel on total extracts with an anti-GR
fic binding of GR was also determined in parallel on RAW 264.7 cells.
without excess unlabeled DEX. Specific binding was determined.
64.7 cells were treated with solvent, DEX alone or Rh1 combined with
in D (0.25, 0.5, 1 ng/ml) in the presence of Rh1. GR mRNA levels were
. The left panel is the quantitative result and the right panel is RNA
; ΔP <0.01 versus Rh1 + DEX group. (D) Protein synthesis was stopped
were determined by Western blot. The detection of β-actin was used as
epresentative of at least two independent induction experiments. DEX,
Figure 5 Effect of Rh1 combined with DEX on GRE activity and some gluconeogenesis-related genes. RAW264.7 cells were treated with
solvent, DEX alone or Rh1 combined with DEX for 24 h. (A) Cell lysates were assayed for luciferase activities. Promoter activities are expressed as
relative induction factor, that is, the ratio of expression levels recorded either at induced and non-induced conditions, with the latter taken to be
1. Assays were performed in triplicate, and results are representative of at least two independent induction experiments. (B) Primary hepatocytes
were treated with solvent, DEX alone or Rh1 combined with DEX for 24 h. RNA was isolated and reverse transcribed. The resulting cDNA was
subjected to PCR analysis with primers to detect the household gene GAPDH (loading control) or the gene coding for DUSP1, PEPCK and G6P in
the same sample. *P <0.01 versus control, #P <0.01 versus DEX group. DEX, dexamethasone; DUSP1, dual specificity protein phosphatase 1; G6P,
glucose-6-phosphatase; GRE, glucocorticoid receptor elements; PEPCK, phosphoenolpyruvate carboxykinasee phosphatase; TNF, tumor
necrosis factor.
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inflammation, Rh1 combined with DEX-treatment showed
a better superiority of anti-inflammatory potential than
DEX treatment alone (Figure 6A).
After clinical assessment for 10 days, mice were sacri-
ficed and paw joints were histologically examined to deter-
mine whether the amelioration of clinical disease activity
was accompanied with reduced histopathological signs of
inflammation and tissue damage. The majority of joints
from vehicle-treated animals showed evidence of the in-
flux of inflammatory cells in marrow cavities and joint
capsules, destruction of articular cartilage and inflam-
mation resulting in periosteal thickening (Figure 6B-b).
In this analysis, only 30% of the joints from the DEX-
treated mice were found to be normal in all assessed
parameters, which still showed inflammatory cells in
marrow cavities and joint capsules, and periosteumthickening (Figure 6B-c). However, Rh1 combined with
DEX treatment group was accompanied by normal his-
topathologic features in all animals. The effects were
most apparent with regard to the reduction in the de-
gree of inflammation in the joint capsules and perios-
teum (Figure 6B-d).
A parallel Real-time PCR for GR mRNA was performed.
GR mRNA after DEX treatment was significantly lower
than those after Rh1 combined with DEX treatment
(P <0.01), and this was reflected by its efficiency in anti-
inflammation in CIA as described in vitro (Figure 6C).
Additionally, effects of Rh1 on blood glucose were also
observed in vivo. High blood glucose levels were found in
the DEX treatment group (P <0.01) but not in the Rh1
combined with DEX group (P >0.05, Figure 6D). Further-
more, by RT-PCR analysis, Rh1 could ameliorate DEX-
induced high expression of the PEPCK or the G-6-P in
Figure 6 Anti-inflammatory potential of ginsenoside Rh1 combined DEX in CIA. (A) After onset of arthritis, CIA mice were randomized in a
PBS, DEX (1 mg/kg) treatment or Rh1 (10 mg/kg) combined with DEX (1 mg/kg) treatment protocol. Disease severity was monitored daily. Dots and bars
represent mean ± SEM. *P <0.05, **P <0.01 compared with PBS, # P <0.05 compared with DEX. (B) Histopathology of paw joints 10 days post-arthritis
onset. HE staining of the metacarpophalangeal joint: a, b, c and d are representative images for blank (normal mice), PBS-, DEX- and Rh1 combined with
DEX-treated mice, respectively. The different parameters assessed are 1) influx of inflammatory cells in joint capsule, 2) cartilage destruction, 3) joint cavity
narrowing, 4) influx of inflammatory cells in marrow cavities, and 5) and periosteal thickening. (C) Real time PCR was performed in parallel on liver tissues
extracts with GR primers. Gene expression of the housekeeping gene GAPDH was used for normalization. *P <0.05, **P <0.01 compared with blank,
##P <0.01 compared with DEX. (D) The blood glucose concentration was determined 6 h after treatment (mice were fasted 18 h before the blood
samples were taken). The normal mice were as blank. Values are expressed as means ± SD. *P <0.01 versus blank??; #P <0.01 versus DEX group. (E) Liver
samples were taken from the CIA mice after 10 days of treatment. PCR analysis with primers detects the household gene β-actin (loading control) or
the gene coding for PEPCK and G6P in the same sample. *P <0.05, **P <0.01 compared with blank, #P <0.05, ##P <0.01 compared with DEX. CIA,
collagen-induced arthritis; DEX, dexamethasone; G6P, glucose-6-phosphatase; GR, glucocorticoid receptor; PBS, phosphate-buffered saline; PEPCK,
phosphoenolpyruvate carboxykinasee phosphatase.
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with DEX had fewer negative effects than DEX treatment
alone on blood glucose in vivo.
Discussion
The present study demonstrates some intriguing mo-
lecular aspects of glucocorticoid receptor biology, which
have to be kept in mind when developing new strategies
to reduce glucocorticoid resistance and related side
effects. The results showed that ginsenoside Rh1 couldimprove the anti-inflammatory potential of DEX even
after prolonged treatment. Most interestingly, Rh1 could
ameliorate DEX- induced hyperglycemia in vitro and
in vivo.
The mechanisms linked to the phenomenon of gluco-
corticoid resistance are complex [4,24]. Several therapeutic
strategies for the management of glucocorticoid-resistant
diseases have been proposed, but most important ap-
proaches involve improving anti-inflammatory potential of
glucocorticoids to reduce treatment time or reversing the
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selective glucocorticoid receptor agonists (SEGRAs; or dis-
sociated steroids) may exert their anti-inflammation with-
out provoking ligand-induced resistance [9]. However, it is
unlikely that SEGRAs will be able to overcome gluco-
corticoid resistance because they might be as ineffective as
conventional glucocorticoids in triggering gene activation
or repression [25]. Alternative anti-inflammatory drugs are
currently available for the treatment of glucocorticoid-
resistant diseases, but these drugs are likely to have issues
with toxicity and side-effects, or are only suitable for to-
pical application [26].
The results presented in this study showed that RAW
264.7 cells were only initially responsive to the therapeutic
effects of DEX after a short-term treatment, but for a pro-
longed time, the cells became insensitive to DEX. When
the cells were treated with DEX combined with Rh1, the
anti-inflammatory potential of DEX was preserved in both
short and prolonged usage. Rh1 itself had no effects on
TNF-induced cytokines, so the heightened anti-inflamma-
tory effect of Rh1 combined with DEX may be attributed
to Rh1’s improvement on GC-GR interaction. In fact, GCs
exhibit potent anti-inflammatory effects through two main
mechanisms. First, they inhibit the transcription of pro-
inflammatory genes via suppression of the transcriptional
activation induced by AP-1 and NFκB. Second, they in-
duce genes that antagonize the inflammatory response, in-
cluding the glucocorticoid-induced leucine zipper (GILZ)
and DUSP1 [26]. Our data showed that in contrast to
DEX, Rh1 combined with DEX still could attenuate p65
cytoplasmic-to-nuclear translocation after prolonged treat-
ment, which is a prerequisite for activation of NFκB, by
decreasing the phosphorylation of IκBα and attenuating
IκBα degradation. Also, Rh1 combined with DEX induced
a higher expression of DUSP1 than DEX alone in either
short-term treatment or prolonged treatment. DUSP1 is a
member of a large family of multifunctional phosphatases
that reside in the nucleus and specifically dephosphorylate
and inactivate members of the MAPK family, such as
JNK, p38 MAPK and ERK [4,24]. Increased expression of
DUSP1 attenuates p38 MAPK signaling, which disrupts
the signal leading to the induction of pro-inflammatory
gene expression. In this report, we demonstrated that de-
phosphorylation of p38 declined after prolonged treatment
with DEX. But Rh1 combined with DEX resulted in stri-
king inhibition of p38 activation even after prolonged
usage, which is accordant to the DUSP1 result. These fin-
dings together show that Rh1 can reinforce the anti-
inflammatory potential of DEX and alleviate GC resistance
induced by prolonged DEX treatment. More importantly,
this improvement was a result of both transrepression and
transactivation of GR. Since down-regulation of GR is as-
sociated with the loss of GCs’ responsiveness, this aspect
was also examined in our study. The results indicated thatRh1 could ameliorate DEX-induced down-regulation of
GR expression and binding, in accordance with the
retained anti-inflammatory effects even after prolonged
treatment. This is in contrast to DEX alone, showing a dir-
ect link between prolonged treatment, decreasing GR and
the abolishment of the anti-inflammatory effects. Further-
more, as Rh1-induced up-regulation of GR was blocked by
the co-treatment with actinomycin-D or cycloheximide, de
novo mRNA transcription and protein synthesis are most
likely involved. These findings suggested that long-term
Rh1 treatment might not only increase the transcription of
GR, but also its synthesis in RAW macrophages. And
Rh1’s up-regulated expression of GR and dephosphory-
lation of p38MAPK might be responsible for its improve-
ment on GR ligand binding. It was reported that activated
p38 targeted the GR ligand-binding domain indirectly to
suppress GR function [27]. Therefore, inhibition of p38
phosphorylation by Rh1 may benefit GR ligand binding.
The role of p38 in the mechanism of action of Rh1 on GR
ligand binding is therefore worthy of further study.
Although Rh1 could increase DEX-induced GRE activa-
tion and DUSP1 expression, Rh1 combined with DEX did
not induce high expression of G-6-P and PEPCK in pri-
mary hepatocytes from mice, which is important in gluco-
neogenesis. It was interesting that Rh1 played different
roles on GRE-driven genes. Therefore, the structural
changes of GR after Rh1 treatment, as well as some tran-
scriptional factors involved require further study. Al-
together, because the most attractive option for treating
glucocorticoid resistance is to directly address the cause,
Rh1 combined with DEX may be an effective treatment
protocol for acquired glucocorticoid resistance with
down-regulation of GR protein levels and binding.
To confirm our in vitro data, we examined the role of
Rh1 combined with DEX in the CIA model. It seems that
Rh1 is able to improve the anti-inflammatory effects of
DEX in vivo. In line with this, improved GR expression
was found in liver isolated from mice treated with Rh1
combined with DEX. Meanwhile, DEX combined with
Rh1 had no unwanted effects on blood glucose levels, in
sharp contrast with the effect of DEX treatment alone.
Further analysis of G6P and PEPCK GRE-driven gene
expression in the liver demonstrated the beneficial regula-
tory effect of Rh1 on glucose metabolism. Although the
CIA model did not mimic GC-resistance in vivo, our data
still supported that Rh1 increased the anti-inflammatory
potential of DEX without hyperglycemia and improved
DEX-induced down-regulation of GR in vivo.
Conclusions
Ginsenoside Rh1 potentiated DEX’s anti-inflammatory ef-
fects by improving DEX-induced down-regulation of GR.
Our data also showed that ginsenoside Rh1 combined
with DEX did not cause hyperglycemia. As a result,
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candidate treatment option for chronic inflammatory dis-
eases that require long-term immunosuppression therap-
ies and so is worthy of study.
Additional files
Additional file 1: Figure S1. Effects of ginsenoside Rh1 on glucocorticoid
receptor (GR). RAW 264.7 cells were treated with solvent (DMSO), DEX (1 μM),
or Rh1 (10 μM, 1 μM and 0.1 μM as indicated in the figures) for 1 h followed
by DEX, for 24 h. (A) Western blot analysis was performed on total protein
extracts with an anti-GR antibody. The detection of β-actin was used as a
loading control. (B) Saturation binding analysis of GR on RAW264.7 cells.
RAW264.7 cells (1×106) were incubated 3 h with 10-6 M [3H] DEX, with or
without excess unlabeled Dex. Specific binding was determined. *P <0.01
versus Control, #P <0.05, ##P <0.01 versus DEX group.
Additional file 2: Figure S2. Rh1 combined with has little cytotoxicity
on RAW264.7 cells. RAW264.7 cells (1 × 104 cells) were pretreated with
either DEX alone or in the presence of 0.1 to 10 μM Rh1 for 24, after that
TNF (20 ng/ml) was added for 8 h. At the end of incubation, cell number
was examined by MTT method. This experiment is representative of three
independent experiments.
Additional file 3: Figure S3. Effects of ginsenoside Rh1 combined with
DEX on p38 activation. After pretreatment with solvent, DEX (1 μM) or
Rh1 (10 μM) combined with DEX for 2 h or 24 h, TNF (20 ng/ml) was
added for the indicated times (15 and 30 minutes) and expression of
phospho-p38 and total p38 was determined by Western blot. The result
was quantified by ImageQuant 5.2. The experiment was replicated three
times, and the result is the average of three experiments. *P <0.01 versus
blank group; #P <0.01 versus TNF group.
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